Tetomilast: new promise for phosphodiesterase-4 inhibitors?

Abstract

INTRODUCTION:

Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for use of tetomilast in the treatment of IBD.

AREAS COVERED:

Peer-reviewed publications, including Phase I and II clinical trials, all other formats included.

EXPERT OPINION:

Tetomilast may be beneficial in IBD. Small differences in molecules and in recombinant proteins can translate into substantial differences in clinical effects and toxicity in IBD. This is a reasonable approach when exploring new options like tetomilast.

• Authors: Stephen J Bickston, Kenneth R Snider, Matthew R Kappus
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 21 Issue 12 Pg. 1845-9 (Dec 2012) ISSN: 1744-7658 [Electronic] England
• PMID: 23043390 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Phosphodiesterase 4 Inhibitors
• Thiazoles
• tetomilast

Topics

• Animals
• Anti-Inflammatory Agents (pharmacology, therapeutic use)
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Phosphodiesterase 4 Inhibitors (pharmacology, therapeutic use)
• Thiazoles (pharmacology, therapeutic use)